0 0 0 0 0.00417151726814132 0.00417151726814132 0.00417151726814132 0.00960419091967413
Sign Up Today X
Thanks for submitting the form.
Stockreport

Mirum doubles down on diversified rare disease strategy [Yahoo! Finance]

Mirum Pharmaceuticals, Inc. - common stock (MIRM)  More Company Research Source: Yahoo! Finance
Last mirum pharmaceuticals, inc. - common stock earnings: 3/12 04:02 pm Check Earnings Report
Rare disease companies often focus on developing just a few products — or even only one — before they're ultimately acquired. “Over the past handful of years now, there were a number of these single-product, rare disease companies, and their end goal really almost had to be to get acquired,” said Chris Peetz, CEO of Mirum Pharmaceuticals. “Because a single rare disease product oftentimes is just not big enough to support all the infrastructure it takes to commercialize the medicine.” Mirum's approach, however, is different, building a larger and more diverse portfolio of several rare disease therapies. The company acquired biotech Bluejay Therapeutics in January, adding the late-stage monoclonal antibody for hepatitis D, brelovitug, to its pipeline. Mirum scored its first FDA approval in 2021 with Livmarli, which treats cholestatic pruritus in patients with the rare genetic liver condition Alagille syndrome. By focusing on “these underserved, smaller medicines that can have a [Read more]
IMPACT SNAPSHOT EVENT TIME: MIRM
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
MIRM alerts
from News Quantified
MIRM
NEWS
MIRM
Earnings
MIRM
Analyst Actions
MIRM
SEC Filings
Stockreport

Mirum doubles down on diversified rare disease strategy [Yahoo! Finance]

Mirum Pharmaceuticals, Inc. - common stock  (MIRM) 
More Company Research Source: Yahoo! Finance
Last mirum pharmaceuticals, inc. - common stock earnings: 3/12 04:02 pm Check Earnings Report
Rare disease companies often focus on developing just a few products — or even only one — before they're ultimately acquired. “Over the past handful of years now, there were a number of these single-product, rare disease companies, and their end goal really almost had to be to get acquired,” said Chris Peetz, CEO of Mirum Pharmaceuticals. “Because a single rare disease product oftentimes is just not big enough to support all the infrastructure it takes to commercialize the medicine.” Mirum's approach, however, is different, building a larger and more diverse portfolio of several rare disease therapies. The company acquired biotech Bluejay Therapeutics in January, adding the late-stage monoclonal antibody for hepatitis D, brelovitug, to its pipeline. Mirum scored its first FDA approval in 2021 with Livmarli, which treats cholestatic pruritus in patients with the rare genetic liver condition Alagille syndrome. By focusing on “these underserved, smaller medicines that can have a [Read more]
IMPACT SNAPSHOT
EVENT TIME:
MIRM
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Don't Miss Out On The Next BIG Stock Move
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS